A groundbreaking daily pill has been shown to double survival time for patients battling the world's deadliest cancer, marking a major advancement in medical research.
Daraxonrasib, a daily oral KRAS inhibitor, doubled median survival in advanced pancreatic cancer patients to 13.2 months versus 6.6 months for chemotherapy, in a 500-patient Phase III trial presented at ASCO 2026. With KRAS mutations driving 90%+ of pancreatic ductal adenocarcinomas, this validates targeted KRAS inhibition as a viable clinical pathway and signals a pipeline shift toward oncology precision medicine investments.
The drug, daraxonrasib, has been hailed as a "gamechanger"
Jun 01, 2026
01:24 pm
What's the storyA new clinical trial has revealed that a daily pill can double the survival time of patients suffering from pancreatic cancer, one of the deadliest forms of the disease.
The drug, daraxonrasib, has been hailed as a "gamechanger" and could revolutionize treatment for this late-diagnosed cancer.
Daily pill can double survival time for world’s deadliest cancer, trial shows
Daily pill almost doubles survival time for pancreatic cancer patients in new trial
'Transformative' pancreatic cancer drug doubles survival time
Why this new pill for a deadly cancer has doctors excited
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. 'I actually started crying' | Fortune
'Game changer' experimental drug doubles survival time for pancreatic cancer, trial shows | CBC News
New drug nearly doubles survival rates in some pancreatic cancer patients, study says
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial
New drug gives extra months of life to pancreatic cancer patients
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer
Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease
People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving…
The results of a clinical trial of a new drug could signal a breakthrough in treating pancreatic cancer
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on…
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer…
